Data investigation

How Much GLP-1 Prices Actually Vary

The dearest tenth of the compounded market charges about three times the cheapest tenth, not the 25x a naive calculation gives. Why the naive number is wrong, and the fifth of sellers who publish no price at all.

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed
7 min read·1 citation

For the same molecule, at the same dose, from sellers who all describe themselves the same way, the dearest tenth of the market charges about three times what the cheapest tenth does. That is the honest figure. The first number we calculated was eight times larger, and the story of why it was wrong is more useful than the number itself.

The spread

Across 572 published monthly prices for compounded semaglutide, from 396 sellers, the ninetieth percentile is 3.0 times the tenth. For compounded tirzepatide, across 506 prices from 365 sellers, it is 2.7 times. The middle half of the market is tighter than people expect: the seventy-fifth percentile sits at roughly 1.3 times the median in both cases.

So this is not a market where identical products cost wildly different amounts at random. It is a market with a reasonably concentrated middle and a long expensive tail — which means the practical question is not “am I being overcharged” so much as “am I in the tail”.

A ratio is the durable way to say this. Any dollar figure we printed would be wrong within months, and every seller’s current number is already on the price tracker with the date we checked it. What does not go stale is the shape: a tight middle, a long upper tail, and a fifth of the market refusing to show you where it sits.

Why our first answer was eight times too big

The naive calculation is minimum against maximum, and it produced a spread of nearly twenty-five times. It was wrong twice over, and both errors are the kind worth recognizing because they recur everywhere prices are compared.

  1. The top of the range was not the same product. The most expensive “compounded” rows were brand-name Ozempic, Wegovy, Mounjaro and Zepbound, recorded with the wrong form. Brand prices against compounded prices is not a comparison, it is a category error.
  2. The bottom of the range was not a monthly price. The cheapest row was a per-vial figure at a starter dose, and its own note says it is not a recurring plan. Set against real monthly plans it makes the market look far cheaper at the floor than it is.
Minimum and maximum are the two least reliable numbers in any dataset. They are, definitionally, the two most likely to be a mistake.

Percentiles fix this, because a single miscoded row cannot move the tenth or ninetieth percentile of five hundred. That is why the corrected figure is a ratio between percentiles rather than between extremes.

What we found in our own data, and fixed

Chasing that top figure turned up a fault on our side. Five pricing rows recorded brand-name products as compounded, and because our scoring benchmarks each seller against the median for its drug and product type, one of them produced a published criticism that was simply wrong: a seller was described as charging 273% above the register median for compounded semaglutide, when the price in question was brand Ozempic, quoted verbatim from the seller’s own site.

The rows are reclassified, the false criticism is gone, and an automated check now fails our build if a brand product is ever priced as compounded again. It is the same discipline we ask of sellers in how to check a review score, applied to a number we generated ourselves.

The fifth of the market you cannot see

111 of 560 sellers publish no price at all — almost exactly a fifth. Their cost appears only after an intake questionnaire, and usually after health information has been submitted.

This matters more than the spread does. A distribution you can measure is one you can shop within; the gated fifth cannot be compared against anything until you have already invested time and handed over medical details. And there is no way to know from outside whether a gated price is high or low — which is, presumably, the point.

If a price appears only after an intake, treat the intake as part of the price. You are paying in personal health information for a number that a competitor published for free, and you will be inside a funnel by the time you see it. Our comparison tool filters to sellers that publish, which is the fastest way to skip that entirely.

How to use this when buying

  • Compare against the median, not against the cheapest. The floor of this market is often a starter dose, a per-vial price or a promotional first month, and none of those is what you will pay ongoing.
  • Check what the price is per, not just what it is. Per vial, per month, per quarter and per starting dose are all quoted the same way.
  • Being above the median is not a scandal. A seller naming its pharmacy, requiring a video visit and answering the phone may be worth more than the cheapest option. Being in the top tenth without offering any of that is the thing to notice.
  • Treat a gated price as a signal in itself. A fifth of sellers do this, and the ones that publish are telling you something before you have spent a minute.

Frequently Asked Questions

Less than the horror stories suggest. Across 572 published monthly prices for compounded semaglutide from 396 sellers, the dearest tenth charges about three times the cheapest tenth, and for tirzepatide about 2.7 times. The middle half of the market is fairly tight; the tail is long and expensive.
Because minimum and maximum are the two values most likely to be errors. When we did that, the top of the range turned out to be brand-name products recorded with the wrong product type and the bottom was a per-vial starter price that its own note said was not a recurring plan. The naive answer was about eight times too large.
111 of the 560 we track publish no price at all — almost exactly a fifth. Their cost appears only after an intake questionnaire, usually after health information has been submitted, so it cannot be compared against anything until you are already in the funnel.
Not for the drug itself, which is the same molecule. It can reflect real differences in service — a named pharmacy, a video visit with a clinician, reachable support. Being above the median is not a scandal; being in the top tenth while offering none of those things is worth noticing.
Yes. Five rows recorded brand-name products as compounded, and one of them produced a published criticism of a seller that was wrong — it compared a brand Ozempic price against the compounded median. The rows are corrected, the criticism is removed, and an automated check now prevents it recurring.

References

  1. 1.GLP Watchdog. Provider register — 572 compounded semaglutide and 506 compounded tirzepatide monthly price rows across 560 sellers, computed August 19, 2026 GLP Watchdog register. 2026. https://glpwatchdog.org/price-tracker

Microdosing a GLP-1: What Evidence Exists

62 of the 560 sellers we track offer a microdose product. The published literature is letters and commentary about how to answer patients who ask for it; we identified no randomized trial.

6 min read

What Makes a Telehealth GLP-1 Prescription Legitimate

The FDA publishes seven warning signs for telehealth medicine sellers, and almost nobody quotes them. Here they are, with what proper prescribing looks like and the one disclosure 139 of our 560 sellers fail.

7 min read

Who Actually Runs Your GLP-1 Brand

61 of the 560 sellers we track name one of just seven shared entities: one white-label platform, two prescriber networks, four compounding pharmacies. Comparing two brands can mean comparing two markups on the same vial.

7 min read

Who Tells You How Your GLP-1 Ships?

192 sellers advertise free shipping. 29 mention keeping it cold. Degraded medication looks exactly like good medication, and the packaging is the only evidence you will ever have.

5 min read

A Quarter as Likely to Be Offered It

People with diabetes who also have a mental health diagnosis received worse care on almost every measure, and a quarter of the odds of being prescribed a GLP-1, while being half again as likely to be put on insulin.

7 min read

Beyond BMI: Who Actually Needs Treatment

Among people all above BMI 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1%. And in trial participants, weight loss was similar across risk groups, so treating by risk costs nothing in effectiveness.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.5

Sesame Care

Oral orforglipron alongside the injectables

8.4

Collective

Flat any-dose pricing, if you can absorb a $199 annual membership on top

8.6

Found

Tirzepatide at $169/month, 37% below the typical price